BL

Bluebird Bio

- NASDAQ:BLUE
Last Updated 2024-04-23

LinkedIn Profile

Access Bluebird Bio historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:blue 1234831 Apr 21st, 2024 12:00AM bluebird bio 131K 593.00 Open Apr 20th, 2024 11:02PM Apr 20th, 2024 11:02PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 20th, 2024 12:00AM bluebird bio 131K 593.00 Open Apr 19th, 2024 11:02PM Apr 20th, 2024 04:39PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 19th, 2024 12:00AM bluebird bio 131K 593.00 Open Apr 18th, 2024 11:11PM Apr 18th, 2024 11:11PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 18th, 2024 12:00AM bluebird bio 131K 593.00 Open Apr 17th, 2024 11:07PM Apr 18th, 2024 05:59PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 17th, 2024 12:00AM bluebird bio 131K 594.00 Open Apr 16th, 2024 10:57PM Apr 17th, 2024 02:23PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 16th, 2024 12:00AM bluebird bio 131K 594.00 Open Apr 15th, 2024 10:49PM Apr 16th, 2024 10:40AM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 15th, 2024 12:00AM bluebird bio 131K 594.00 Open Apr 14th, 2024 10:50PM Apr 15th, 2024 04:21PM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 14th, 2024 12:00AM bluebird bio 131K 591.00 Open Apr 13th, 2024 10:42PM Apr 14th, 2024 10:40AM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 13th, 2024 12:00AM bluebird bio 131K 591.00 Open Apr 12th, 2024 10:32PM Apr 13th, 2024 11:08AM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology
nasdaq:blue 1234831 Apr 12th, 2024 12:00AM bluebird bio 131K 591.00 Open Apr 11th, 2024 10:36PM Apr 12th, 2024 08:03AM bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines Open gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy Open 60 Binney Street Cambridge Massachusetts US 02142 Bluebird Bio Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.